Bio-Rad Laboratories Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Bio-Rad Laboratories Inc Stock Forecast and Price Target
Year-long price target forecasts from prominent analysts have recently been released for Bio-Rad Laboratories Inc, with an average price target of $436.70. This potential gain of 56.97 percent from the previous closing price in April, 2024 is calculated on a high forecast of $474.00 and a low estimate of $365.00. If you're thinking of investing in BIO stock, it might be good to look at its rivals too.
56.97% Upside
Bio-Rad Laboratories Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Bio-Rad Laboratories Inc's Price has decreased from $449.10 to $0.00 – a 100.00% drop! In the next year, analysts predict that Fair Value will reach $508.86 – an increase of 100.00%. For the next nine years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$577.39 | Buy/Sell | $591.94 | 6.51% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$250.41 | Buy/Sell | $260.33 | 7.82% |
| A Stock Forecast | Agilent Technologies | Outperform |
10
|
$137.49 | Buy/Sell | $138.82 | 10.19% |
| MTD Stock Forecast | Mettler-Toledo International | Hold |
13
|
$1.24k | Buy/Sell | $1.12k | -0.43% |
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$122.87 | Buy/Sell | $159.28 | 22.08% |
Bio-Rad Laboratories Inc Revenue Forecast for 2023 - 2025 - 2030
Bio-Rad Laboratories Inc's Revenue has grown in the last three years, jumping from $2.55B to $2.67B – an increase of 4.94%. In the next year, analysts predict that Revenue will reach $2.74B – an increase of 2.50%. For the next eight years, the forecast is for Revenue to grow by 6.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| WAT Stock Forecast | Waters | Hold |
15
|
$310.25 | Buy/Sell | $323.50 | 6.37% |
| AVTR Stock Forecast | Avantor | Outperform |
16
|
$25.46 | Buy/Sell | $23.25 | 9.98% |
| PKI Stock Forecast | PerkinElmer | Outperform |
16
|
$102.68 | Buy/Sell | $121.84 | 21.62% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BRKR Stock Forecast | Bruker | Outperform |
16
|
$82.20 | Buy/Sell | $73.64 | 10.10% |
| COHR Stock Forecast | Coherent | - |
12
|
$33.97 | Buy/Sell | $258.00 | -100.00% |
| PACB Stock Forecast | Pacific Biosciences of Califor... | Outperform |
9
|
$1.36 | Buy/Sell | $12.67 | 157.35% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LAB Stock Forecast | Standard BioTools | Buy |
11
|
$2.42 | Buy/Sell | $4.00 | 44.63% |
| HBIO Stock Forecast | Harvard Bioscience | Buy |
14
|
$3.69 | Buy/Sell | $7.00 | 89.70% |
| EQTL Stock Forecast | Equitech International | - |
0
|
$1.40 | Buy/Sell | $0.00 | -100.00% |
Bio-Rad Laboratories Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Bio-Rad Laboratories Inc's EBITDA has fallen from $546.86M to $483.75M – a 11.54% decrease. In the next year, analysts expect EBITDA to reach $552.79M – an increase of 14.27%. For the next eight years, the forecast is for EBITDA to grow by 26.86%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ASPT Stock Forecast | Haber | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| MDIT Stock Forecast | Medite Cancer Diagnostics | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| OMRX Stock Forecast | Orthometrix | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
Bio-Rad Laboratories Inc EBIT Forecast for 2023 - 2025 - 2030
Bio-Rad Laboratories Inc's EBIT has decreased In the last three years, from $408.76M to $337.80M – a 17.36% drop. The next year looks promising for Bio-Rad Laboratories Inc, with analysts predicting EBIT of $410.68M – an increase of 21.57%. Over the next eight years, experts anticipate that Bio-Rad Laboratories Inc's EBIT will grow at a rate of 44.13%.
Bio-Rad Laboratories Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Bio-Rad Laboratories Inc's EPS has decreased from $10.52 to $0.00 – a 100.00% drop! In the next year, analysts predict that EPS will reach $11.92 – an increase of 100.00%. For the next nine years, the forecast is for EPS to grow by 100.00%.
Site Navigation
.jpg)